Structure Therapeutics reports best-in-class weight loss with oral GLP-1 candidate aleniglipron

Structure Therapeutics announced that its oral GLP-1 drug candidate aleniglipron achieved a 16% weight loss in clinical testing, marking the highest efficacy reported for an oral GLP-1 treatment to date. The company is preparing to advance aleniglipron into phase 3 trials.